Education
About Us
Working with TipRanks
Follow Us
Larimar Therapeutics, Inc. (LRMR)
NASDAQ:LRMR
LRMR Stock Chart & Stats
$3.65
-$0.11(-2.78%)
At close: 4:00 PM EST
$3.65
-$0.11(-2.78%)
Day’s Range― - ―
52-Week Range$1.61 - $5.37
Previous CloseN/A
Volume147.46K
Average Volume (3M)1.43M
Market Cap
$312.40M
Enterprise Value$81.90M
Total Cash (Recent Filing)$175.44M
Total Debt (Recent Filing)$4.35M
Price to Earnings (P/E)―
Beta1.85
Next Earnings
Mar 18, 2026EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding85,590,390
10 Day Avg. Volume1,145,552
30 Day Avg. Volume1,426,427
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.38
Price to Sales (P/S)0.00
P/FCF Ratio-3.33
Enterprise Value/Market Cap0.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-468.01
Enterprise Value/Ebitda-0.60
Forecast
1Y Price Target
$18.00Price Target Upside393.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.95
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Efficacy And ImprovementFunctional improvement from baseline on clinical endpoints was observed with nomlabofusp treatment out to one year, which is divergent from FA-COMS natural history and has not been observed before in an FA interventional trial.
Regulatory InteractionNomlabofusp is part of the FDA START program, and the company is having regular agency interactions, which could provide investor confidence.
Therapy AdvancementsThis quarter saw meaningful advancements in Larimar’s frataxin replacement therapy program, nomlabofusp (nomla), for Friedreich’s ataxia (FA).
Bears Say
Market ReactionLarimar shares are down about 30%, related to commentary regarding the tolerability profile of nomlabofusp and the resultant protocol change.
Regulatory ChallengesShares are trading down ~14% in sympathy to negative regulatory news from UniQure and Biohaven, with the FDA questioning the validity of external natural history comparisons for demonstration of efficacy in rare neurological disorders.
Safety ConcernsAnaphylaxis remains a key debate concerning the safety of nomlabofusp.
Larimar Therapeutics News
LRMR FAQ
What was Larimar Therapeutics, Inc.’s price range in the past 12 months?
Larimar Therapeutics, Inc. lowest stock price was $1.61 and its highest was $5.37 in the past 12 months.
What is Larimar Therapeutics, Inc.’s market cap?
Larimar Therapeutics, Inc.’s market cap is $312.40M.
When is Larimar Therapeutics, Inc.’s upcoming earnings report date?
Larimar Therapeutics, Inc.’s upcoming earnings report date is Mar 18, 2026 which is in 88 days.
How were Larimar Therapeutics, Inc.’s earnings last quarter?
Larimar Therapeutics, Inc. released its earnings results on Nov 05, 2025. The company reported -$0.61 earnings per share for the quarter, missing the consensus estimate of -$0.404 by -$0.206.
Is Larimar Therapeutics, Inc. overvalued?
According to Wall Street analysts Larimar Therapeutics, Inc.’s price is currently Undervalued.
Does Larimar Therapeutics, Inc. pay dividends?
Larimar Therapeutics, Inc. does not currently pay dividends.
What is Larimar Therapeutics, Inc.’s EPS estimate?
Larimar Therapeutics, Inc.’s EPS estimate is -0.5.
How many shares outstanding does Larimar Therapeutics, Inc. have?
Larimar Therapeutics, Inc. has 85,590,390 shares outstanding.
What happened to Larimar Therapeutics, Inc.’s price movement after its last earnings report?
Larimar Therapeutics, Inc. reported an EPS of -$0.61 in its last earnings report, missing expectations of -$0.404. Following the earnings report the stock price went down -15.263%.
Which hedge fund is a major shareholder of Larimar Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LRMR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Larimar Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.00 (393.15% Upside)
$18.00 (393.15% Upside)
Blogger Sentiment
Bullish
LRMR Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 10.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.1%
Last 30 Days ▼ 8.8%
Last 30 Days ▼ 8.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-17.54%
12-Months-Change
Fundamentals
Return on Equity
-78.24%
Trailing 12-Months
Asset Growth
-14.46%
Trailing 12-Months
Company Description
Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc. (LRMR) is a clinical-stage biotechnology company focused on developing treatments for rare, complex diseases. The company is headquartered in the United States and operates within the pharmaceutical and biotechnology sectors. Its core product is CTI-1601, a novel protein replacement therapy designed to address Friedreich's ataxia, a debilitating genetic disorder. Larimar Therapeutics is committed to advancing its pipeline of therapeutics to improve the lives of patients with unmet medical needs.
LRMR Stock 12 Month Forecast
Average Price Target
$18.00
▲(393.15% Upside)
Technical Analysis
Omeros
―
Vanda
―
Foghorn Therapeutics
―
Candel Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
Currently, No data available
---